KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Current Deferred Revenue (2016 - 2018)

Gsk (GSK) has 3 years of Current Deferred Revenue data on record, last reported at $277.9 million in Q4 2018.

  • For Q4 2018, Current Deferred Revenue fell 12.77% year-over-year to $277.9 million; the TTM value through Dec 2018 reached $277.9 million, down 12.77%, while the annual FY2018 figure was $288.5 million, 6.69% down from the prior year.
  • Current Deferred Revenue reached $277.9 million in Q4 2018 per GSK's latest filing, down from $318.6 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $318.6 million in Q4 2017 and bottomed at $196.4 million in Q4 2016.
  • Average Current Deferred Revenue over 3 years is $264.3 million, with a median of $277.9 million recorded in 2018.
  • Peak YoY movement for Current Deferred Revenue: skyrocketed 62.22% in 2017, then decreased 12.77% in 2018.
  • A 3-year view of Current Deferred Revenue shows it stood at $196.4 million in 2016, then skyrocketed by 62.22% to $318.6 million in 2017, then dropped by 12.77% to $277.9 million in 2018.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $277.9 million in Q4 2018, $318.6 million in Q4 2017, and $196.4 million in Q4 2016.